Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma
dc.contributor.author | Slavik, Milan | en_US |
dc.contributor.author | Liu, P. Y. | en_US |
dc.contributor.author | Kraut, Eric H. | en_US |
dc.contributor.author | Natale, Ronald B. | en_US |
dc.contributor.author | Flaherty, Lawrence E. | en_US |
dc.contributor.author | Sondak, Vernon K. | en_US |
dc.date.accessioned | 2006-09-11T15:46:11Z | |
dc.date.available | 2006-09-11T15:46:11Z | |
dc.date.issued | 1995-06 | en_US |
dc.identifier.citation | Slavik, Milan; Liu, P. Y.; Kraut, Eric H.; Natale, Ronald B.; Flaherty, Lawrence E.; Sondak, Vernon K.; (1995). "Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma." Investigational New Drugs 13(2): 143-147. <http://hdl.handle.net/2027.42/45186> | en_US |
dc.identifier.issn | 0167-6997 | en_US |
dc.identifier.issn | 1573-0646 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45186 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8617577&dopt=citation | en_US |
dc.description.abstract | Merbarone, NSC 336628, is an investigational anticancer drug with activity against experimental animal tumors including melanoma. This paper presents results of a Phase II clinical study of merbarone in patients with biopsy proven stage IV malignant melanoma without prior chemotherapy and with no evidence of CNS involvement. Thirty-five patients with median age 58 (range 27–81), with performance status 0–2 were treated with merbarone 1000 mg/m 2 /day for five days by intravenous continuous infusion repeated every 3 weeks. All patients (21 males and 14 females) were evaluable for toxicity. Two patients were not evaluable for response having been removed from protocol treatment due to toxicity and received other treatment during the first course of chemotherapy. Among the evaluable patients there was one complete response in a supraclavicular lymph node lasting four months and one partial liver response lasting three months. The remaining thirty-one patients were non-reponders. Of these one had a stable disease lasting 21 months. The overall objective response rate was 6% (2/35) with a 95% confidence interval of 1%–19%. Twenty-six of the 35 patients have died. The estimated median survival of the entire group was 9 months with a 95% confidence interval of six to eleven months. Renal toxicity was dose-limiting and manifested as increasing serum creatinine (54% of patients), proteinuria (51%) and hematuria (9%). One patient experienced grade 4 creatinine increase, proteinuria and acute renal failure. Other toxicities included nausea (71%), vomiting (51%), malaise (23%), weakness (20%), alopecia (17%), diarrhea (17%), anorexia (14%), transaminase (SGOT, SGPT) increase (14%), constipation (14%), alkaline phosphatase or 5′nucleotidase increase (9%), and fever (9%). Hematologictoxicity (granulocytopenia, leukopenia, and anemia) was generally mild and infrequent (29%, only one patient had grade 4 granulocytopenia). Overall 9 patients (26%) had at least one grade 3 toxicity. We conclude that merbarone at this dose and schedule has detectable but minimal activity in the treatment of metastatic malignant melanoma and given the significant renal toxicity this schedule does not merit further evaluation in this disease. | en_US |
dc.format.extent | 411334 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Merbarone | en_US |
dc.subject.other | Phase II Clinical Study | en_US |
dc.subject.other | Malignant Melanoma | en_US |
dc.title | Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan School of Medicine, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Wichita CCOP, University of Kansas School of Medicine-Wichita, Wichita, Kansas; Department of Veterans Affairs Medical Center, Wichita, Kansas; Medical Service, Department of Veterans Affairs Medical Center, University of Kansas School of Medicine-Wichita, 5500 E. Kellogg, 67218, Wichita, Kansas, USA | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center and Fred Hutchinson Cancer Research Center, Seattle, Washington | en_US |
dc.contributor.affiliationother | Ohio State University School of Medicine, Columbus, Ohio | en_US |
dc.contributor.affiliationother | University of Southern California School of Medicine, Los Angeles, California | en_US |
dc.contributor.affiliationother | Wayne State University School of Medicine, Detroit, Michigan | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8617577 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45186/1/10637_2004_Article_BF00872863.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00872863 | en_US |
dc.identifier.source | Investigational New Drugs | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.